Skip to main content
Journal cover image

Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine.

Publication ,  Journal Article
Talbot, HK; Keitel, W; Cate, TR; Treanor, J; Campbell, J; Brady, RC; Graham, I; Dekker, CL; Ho, D; Winokur, P; Walter, E; Bennet, J ...
Published in: Vaccine
July 29, 2008

To augment the available influenza vaccine supply, a phase III study was conducted to evaluate the immunogenicity, safety, and consistency of a new trivalent inactivated influenza vaccine manufactured by CSL Limited. Healthy adults (ages 18-64) were randomized to receive either a single dose of TIV from multi-dose vials with thimerosal, TIV from pre-filled syringes without thimerosal, or placebo. Of the TIV recipients, 97.8% achieved a post-vaccination titer > or =40 against H1N1, 99.9% against H3N2 component, and 94.2% against influenza B. Few local or systemic adverse events were noted after vaccination with either TIV presentation. TIV was well tolerated and immunogenic.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Vaccine

DOI

ISSN

0264-410X

Publication Date

July 29, 2008

Volume

26

Issue

32

Start / End Page

4057 / 4061

Location

Netherlands

Related Subject Headings

  • Young Adult
  • Virology
  • Vaccines, Inactivated
  • Thimerosal
  • Middle Aged
  • Male
  • Influenza, Human
  • Influenza Vaccines
  • Influenza B virus
  • Influenza A Virus, H3N2 Subtype
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Talbot, H. K., Keitel, W., Cate, T. R., Treanor, J., Campbell, J., Brady, R. C., … Edwards, K. M. (2008). Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine. Vaccine, 26(32), 4057–4061. https://doi.org/10.1016/j.vaccine.2008.05.024
Talbot, H Keipp, Wendy Keitel, Thomas R. Cate, John Treanor, James Campbell, Rebecca C. Brady, Irene Graham, et al. “Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine.Vaccine 26, no. 32 (July 29, 2008): 4057–61. https://doi.org/10.1016/j.vaccine.2008.05.024.
Talbot HK, Keitel W, Cate TR, Treanor J, Campbell J, Brady RC, et al. Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine. Vaccine. 2008 Jul 29;26(32):4057–61.
Talbot, H. Keipp, et al. “Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine.Vaccine, vol. 26, no. 32, July 2008, pp. 4057–61. Pubmed, doi:10.1016/j.vaccine.2008.05.024.
Talbot HK, Keitel W, Cate TR, Treanor J, Campbell J, Brady RC, Graham I, Dekker CL, Ho D, Winokur P, Walter E, Bennet J, Formica N, Hartel G, Skeljo M, Edwards KM. Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine. Vaccine. 2008 Jul 29;26(32):4057–4061.
Journal cover image

Published In

Vaccine

DOI

ISSN

0264-410X

Publication Date

July 29, 2008

Volume

26

Issue

32

Start / End Page

4057 / 4061

Location

Netherlands

Related Subject Headings

  • Young Adult
  • Virology
  • Vaccines, Inactivated
  • Thimerosal
  • Middle Aged
  • Male
  • Influenza, Human
  • Influenza Vaccines
  • Influenza B virus
  • Influenza A Virus, H3N2 Subtype